Efavirenz as Second-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer


NCT00964171

Interventional

Phase 2

Unknown status
RATIONALE: Efavirenz may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well efavirenz works as second-line therapy in treating patients with metastatic pancreatic cancer.
Aug 31,2008
All
18 Years
N/A
72

In order to facilitate the use of our website, we use cookies.

Please confirm if you accept our tracking cookies. When declining the cookies, you can continue visiting the website without sending data to third party services. Read our complete cookie statement here.